Journal: Journal of Medicinal Chemistry
Article Title: Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity
doi: 10.1021/acs.jmedchem.5c01111
Figure Lengend Snippet: Degradation of CDK9 by 13 and 14 (dCDK9-202) across multiple cell lines. (A–D) Examination of dose-dependent CDK9 degradation by 13 and 14 (dCDK9-202) in TC-71, U87, SKUT1, and RH5. Cells were treated with increasing concentrations of indicated compounds for 6 h. (E) Effects of 22 on CDK9 protein. TC-71 cells were treated with the indicated concentration of 22 for 6 h.
Article Snippet: TC-71 (DSMZ), A673 (A-673, ATCC), SJSA-1 (ATCC), A-375 (ATCC), MES-SA (ATCC), U87 (U-87MG, ATCC), MDA-MB-231 (ATCC), and SKUT1 (SK-UT-1, ATCC) cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich).
Techniques: Concentration Assay